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www.cdatm.orgAbstractObjective: To determine the sensitivity and significance of B-cell chimerism for the detection of early engraftment, transplant
rejection, and disease relapse.
Methods: The dynamic monitoring of lineage-specific cell subtypes (B, T, and NK cells) was made in 20 B-cell acute lympho-
blastic leukemia (B-ALL) patients following allogeneic hematopoietic stem cell transplantation (allo-HSCT). In the early period
after allo-HSCT, the latest establishment of B-cell complete chimerism (CC) was observed in a majority of patients.
Results: The percentage of donor cells of B-cell lineage was lower than the percent of T-cell lineage in most of the mixed
chimerism (MC) patients. During graft rejection, the frequency of patients with decreasing MC of B-, T- and NK-cell lineage were
5/5, 2/5, and 2/5. When disease relapsed, five patients showed a faster decrease of the donor percent of B-cells than of T- or NK-
cells. Only one patient displayed a more rapid decrease in NK-cells than in T- or B-cells.
Conclusion: Monitoring of B-cell chimerism after HSCT seems to be valuable for insuring complete engraftment, anticipating
graft rejection, and relapse in B-ALL patients.
© 2015 Chinese Medical Association. Production and hosting by Elsevier B.V. on behalf of KeAi Communications Co., Ltd. This is
an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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ALL can be of either T or B cell lineage, roughly 75%
of cases of adult ALL are of B-cell lineage. Allogeneic
hematopoietic stem cell transplantation (allo-HSCT) is
the most promising curative treatment for adults with
ALL. However, the cure rate with transplantation has
not been satisfactory. Frequent monitoring of mixed
chimerism after allo-HSCT is clinically useful sinceElsevier B.V. on behalf of KeAi Communications Co., Ltd. This is an
ons.org/licenses/by-nc-nd/4.0/).
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versus-host disease (GVHD), graft loss, or relapse.
The methods commonly used for chimerism analysis
include fluorescence in situ hybridization (FISH), vari-
able number of tandem repeats (VNTR) or short tandem
repeat (STR), Y chromosome analysis, and quantitative
real-time PCR (qPCR).1e3 Polymerase chain reaction
(PCR) amplification of STR loci is currently the most
commonly accepted and most widely used method for
assessment of engraftment and mixed chimerism after
HSCT. Although whole peripheral blood (PB) or bone
marrow (BM) is most often used for chimerism anal-
ysis, it is important to realize that patients could show
complete chimerism (CC) for one cell type, for example
T-cells, whereas other cell types could be totally or in
part recipient-derived.4,5 This is called split chimerism
(SC). Many studies have examined the prognostic value
of the level of mixed chimerism in different cellular
subsets, such as T-cells and NK-cells. So it is important
to evaluate the kinetics of mixed chimerism (MC) in
different cell lineages post-HSCT.6,7
As engraftment is a dynamic process with variable
kinetics among individuals, and the dynamics of this
variability are not well understood. In previous studies,
there have been quite a few reports about SC or discrepant
results among various cell lineages in B-ALL patients
post-HSCT. To understand these issues, we analyzed 19Table 1
Patient characteristics.
Patient no. TBI (GY)
before
HSCT
Disease status
before HSCT
Gender/
age
aGVHD
1 6 NR M/36 e/2
2 8 CR2 M/23 e
3 6 CR1 F/16 III/1
4 6 CR1 F/54 I/1
5 6 CR1 F/20 I/1
6 6 CR1 M/20 II/0
7 6 NR M/28 II/0
8 8 NR F/30 I/0
9 8 CR2 F/42 II/1
10 8 NR M/34 III/0
11 10 CR1 M/22 III/2
12 6 CR1 M/53 e
13 10 CR1 M/33 I/1
14 10 NR F/32 II/0
15 10 CR1 F/21 IV/0
16 10 CR1 M/21 III/0
17 10 NR M/34 I/0
18 10 NR F/29 III/0
19 10 NR M/10 I/1
20 8 CR1 F/46 I/0
CR1: first complete remission; CR2: second complete remission; NR: nonr
2: extensive; MUD: matched unrelated donor; MRD: matched related donoadult patients and one ten-year-old boy with B-ALL who
received allo-HSCT between 2007 and 2012. We
compared lineage-specific cell subtypes, namely, B-cells,
T-cells, and NK-cells, after allo-HSCT by using multi-
plex STR-PCR in order to determine the sensitivity and
significance ofB-cell chimerism for the detection of early
engraftment, transplant rejection, and disease relapse.
Materials and methods
Patients
A total of 19 adults and one ten-year-old boy with
B-ALL who received allo-HSCT between August 2007
and September 2012 were included in this study. The
median age was 30 years old (16e54 years old), and
the group was comprised of eleven males and nine
females. Disease status at the time of transplantation
was based on marrow morphology: 10 patients were in
first remission, two were in second remission, and eight
were in relapse. The donors were 16 human leukocyte
antigen (HLA)-matched unrelated (MUD 75%), 2
HLA-matched related (MRD, 10%), one sibling-
matched (the boy), and one HLA-haploidentical. Six
patients were transplanted with sex-mismatched grafts.
Patient characteristics are summarized in Table 1.
Additionally, another three adult patients with T-ALL,/c grade Causes
of death
Graft type/Donor HLA
matching
Survival
(months)
cGVHD MUD 9/10 41.5
e MUD 10/10 58þ
Relapse MUD 9/10 22
e MUD 8/10 52þ
Relapse MUD 10/10 32
Relapse MUD 8/10 23
Relapse MUD 9/10 6
Relapse Haploidentical 4/6 3
e MUD 9/10 37þ
Fail MUD 8/10 4
cGVHD MUD 9/10 5
Relapse MRD 10/10 3
e MUD 8/10 33þ
Relapse MUD 8/10 25
aGVHD MUD 8/10 3
e MUD 10/10 24þ
Relapse MRD 10/10 9
aGVHD MUD 8/10 4
e Sibling 10/10 5þ
e MUD 10/10 4þ
emission; cGVHD (according to IBMTR); 0: no cGVHD; 1: limited;
r.
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received myeloablative transplantation were also
included in our analysis.
Intervals of analysis
For chimerism analysis, BM samples were collected
from the donor and recipient before the transplantation
and from the recipient on days 14 and 28 and at 1.5 and
2 months, then monthly or every two months there-
after. BM aspirates were collected in EDTA at the in-
tervals described above. Mononuclear marrow cells
were isolated by Ficoll-Hypaque density gradient
centrifugation and washed twice in phosphate-buffered
saline.
Conditioning therapy and GVHD prophylaxis
The conditioning regimen consisted of Teniposide
(VM26, 15 mg$kg-1$ d-1 from days 6 to 2 for each
patient for 2e3 days), Cyclophosphamide (CTX,
60 mg/kg/d from days 6 to 3 for each patient for 2
days), Antithymocyte globulin (ATG, 2.5 mg/kg/d from
days 5 to 2), and 6e10 Gy of Total body irradiation
(TBI) was delivered in fractions of 2e3 Gy each for
2e3 days (days 3 to 1). All patients received pro-
phylaxis to prevent GVHD; CSA at a dose of 2 mg/kg
was administered intravenously from days 3, MTX
15 mg/m2 on Day 1, and 10 mg/m2 on Days 3 and 6.
Flow cytometric analysis and cell sorting
To evaluate lineage-specific chimerism, selection of
CD3 (T cells), CD16/CD56 (NK cells), and CD19 (B
cells) from BM samples were collected by four-color
quantitative flow-cytometric (FACS) analysis on a
FACSVantage SE (Becton, Dickinson and Company,
USA). The percentage of B-cells in PB is lower than in
BM, especially in the early period after HSCT, so BM
samples were used to separate B from T and NK cells.
Chimerism was detected at the first appearance of
leukocyte counts adequate for cell sorting from days
þ14 following HSCT. The number of target cells
sorted for subsequent PCR analysis ranged between
0.5  103 and 3  105 and the purity of each cell
lineage was verified by flow cytometry (>95%).
Chimerism analysis
DNA was extracted from sorted cells using the
QIAamp DNA Blood Mini Kit and QIAamp Investi-
gator kit (Qiagen, Hilden, Germany). The finalconcentration of DNA was 0.02e0.2 ng per PCR.
Chimerism studies were performed using the AmpF/
STR Identifiler PCR Amplification Kit (Applied Bio-
systems, Foster City, CA, USA). The PCR products
were analyzed using ABI 3130xl Genetic Analyzer
(Applied Biosystems). Fluorescence was quantified,
and the precise size of the DNA fragments was
calculated with Genemapper software 3.2 (Applied
Biosystems). The percentage of donor and recipient
DNA was calculated from individual proportions of
donor and recipient peak areas in relation to the sum-
mation of all signals from each pair of informative
STR markers. The unique STR loci of the donor and
recipient were used to evaluate chimerism. And a loci
that had a stutter peak that was neither one repeat
smaller (n  1) nor one repeat larger (n þ 1) than the
allele peak was excluded.8e10
Definition of engraftment, chimerism status and relapse
Myeloid engraftment was defined as the first of
three consecutive days with an absolute neutrophil
count (ANC) above 0.5  109/L. Platelet engraftment
was defined as the first of seven consecutive days with
a platelet count exceeding 20  109/L without platelet
transfusion.11,12 Acute GVHD was graded from I to IV.
The diagnosis of acute GVHD was based on clinical
symptoms and/or biopsies from skin, oral mucosa, liver
or gut. Chronic GVHD was assessed in patients alive
after three months, and graded from 0 to 2.
CC was defined as the presence of only donor cells
at all time points post-HSCT.13,14 The variable change
of donor% (percentage of donor) over 5% was defined
as increasing or decreasing MC. Relapse was defined
as the appearance of more than 5% blasts in the BM or
new extramedullary leukemic lesions.
Results
Outcomes in patients
All patients received a myeloablative conditioning
regimen, which included 6e10 Gy TBI, followed by
infusion of allogeneic unmanipulated stem cells. The
follow-up period of the 20 patients at the date of
analysis ranged from 3 to 58 months. The overall
survival (OS) is different between patients who
received 6 and 8e10 Gy TBI (1/7 vs. 6/13). Before
allo-HSCT, a complete remission (CR) was achieved in
12 patients, whereas eight patients showed progressive
disease. In the patients with CR before HSCT, the OS
(6/12) was better than those not in remission (NR, 1/8).
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HSCT; 8/13 died of hematologic relapse (range 3e32
months, median 15.5 months) and four experienced
transplant-related complications (range 3e41.5
months, median 4.5 months). The other patient (patient
No. 10) was excluded from our analysis due to primary
graft failure: donor cell hematopoiesis was not seen, B/
T/NK chimerism <25% on þ14 days, donor cells of
the three lineages were not detected on þ28 days and
the patient died at þ4 months.
The remaining seven patients who were alive at the
date of analysis had survived a median of 33 months
(ranged from 4 to 58 months). Among these seven
surviving patients, patient No. 4 experienced disease
relapse at þ44 months and then received
chemotherapy.
Except for patient No. 10, the median time to reach
a white blood cell (WBC) count >0.5  109/L was
þ13 days (10e29 days). The median time to reach a
platelet count >20  109/L was þ13 days (9e34
days). Acute GVHD developed in 17 patients (Grade
IeII in 11 patients and Grade IIIeIV in six patients).
Among the 17 patients who survived more than 100
days after transplantation, eight developed chronic
GVHD.
Pattern of chimerism of different lineages in the early
post-transplant period
On þ14 days after SCT, as mentioned above, pa-
tient No. 10 experienced graft failure. Lymphocytic
subpopulations could not be sorted in patient No. 12
who lacked enough white blood cells. Among the
remaining 18 patients, the median B-cell, T-cell and
NK-cell chimerism was 81.6%, 93.8% and 99.2%,
respectively (Table 2). The number of patients with CC
in the B-, T- and NK-cell compartments was 3/18, 4/Table 2
Chimerism in different lineages in the early post-transplant period.
Lineage
chimerism
B T NK Totally B later
than T
B earlier
than T
B and T
almost
equal
MC CCMCCCMCCC
14 days 15 3 14 4 5 13 18a 12 3 3
28 days 7 12 3 16 e 19 19 6 2 11
1.5 months 5 14 2 17 e 19 19 4 1 14
2 months 5 14 2 17 2 17 19 5 e 14
MC: mixed chimerism; CC: complete chimerism; the ratio is donor%
chimerism.
a Patient No. 10 experienced primary graft failure, cell counts is too
low to be detected on day 14 in patient No. 12, totally 18 patients are
summarized on day 14.18, and 13/18, respectively. Within MC patients the
percentage of donor cells of B- and T-cell lineages
were much lower than those of NK-cell lineage.
Among these 18 patients, the chimeric ratio of donor%
is lower for B-cells than for T-cells in 12 patients. But
we also found three patients that have a higher donor%
of B-cells than of T-cells, and three patients who had a
similar donor% of the two cell lineages.
On 28 day, in 19 patients, the median B-cell, T-cell
and NK-cell chimerism was 97.3%, 98.9% and 100%
(Table 2). The frequency of patients with CC in the B-,
T- and NK-cell compartments were 12/19, 16/19 and
19/19, respectively. Among these 19 patients, six pa-
tients had a significantly lower donor cell percentage of
B-cells than of T-cells and two patients had a higher
donor cell percentage of B-cells than of T-cells. The
remaining 11 patients had similar donor cell engraft-
ment levels of B-cells and T-cells.
At þ1.5 months, CC of the NK-cells was achieved
in all 19 patients, but MC still could be seen in the B-
cell and T-cell lineages (five patients with B-cell MC
versus two patients with T-cell MC, Table 2). Four of
the five SC patients showed a lower percentage of
donor cells in the B-cell compartment than in the T-cell
compartment, the remaining one patient showed
opposite results.
At þ2 months, 14 patients were observed with full
donor chimerism in all fractions. The other four pa-
tients displayed decreasing MC in their B-cells, and
two of them also showed concurrent donor% decreases
in T-cells and NK-cells (Table 2 and Fig. 1). Only one
patient (No. 20) did not show CC in the B-cell
compartment until þ3 months, while their T-cells and
NK-cells had already developed stable CC at þ1
month.14d 28d 1.5m 2m
75
80
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100
m
ed
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n 
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r %
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 NK
Fig. 1. Evolution of B/T/NK cell chimerism in the early post-HSCT
period.
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Fig. 3. Disease evolution in patient No. 6. Relapsed at þ9 months
and received three times DLI between þ11 and þ11.5 months.
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Graft rejection was experienced in five patients. Four
of themwere observedwith a decreasing donor% in their
B-cell lineage at þ2 months, and 2/4 patients also
showed decreasing chimerism in the T-cell and NK-cell
lineages. There was a more obvious donor% decrease in
B-cells than in the other two cell lineages. In patient
No.1, a decreasing donor% of B cells was seen at þ3,
þ5.5, þ10.5, þ15.5 and þ22 months, while T and NK
cell lines retained stable CC expression.
Up to the time of analysis, eight patients experi-
enced hematologic relapse and died. Two of them (No.
8 and No. 12) died too soon to be further monitored;
both died at þ3 months. A discrepancy of decreasing
donor% between B and T/NK cell lineages was seen in
5/6 remaining patients. They displayed a much greater
decrease in donor% in the B-cell compartment than in
the T/NK-cell compartments. Three of the six patients
received further therapy. Patient No. 5 received a
haploidentical transplantation at þ10.5 months, and
relapsed again at þ17.5 months and immediately
received chemotherapy (Fig. 2). Patient No. 6 received
three times of donor lymphocyte infusions (DLIs)
(Fig. 3). Patient No. 14 received chemotherapy
(Fig. 4). A different pattern of lineage dynamic
chimerism after treatment were observed in these three
patients. No. 5, No. 6, and No. 14 is shown in Figs.
2e4. The other three patients gave up further therapy
after disease relapse (No. 3, No. 7 and No. 17).
Another patient (No. 4) relapsed at þ44 months, but
was still alive at the time of writing. Compared with T
and B cell lineages, chimerism analysis showed a
significant decrease of the donor cell percentage of NK
cells.8 10 12 14 16 18 20
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Haploidentical transplantation chemotherapy
Fig. 2. Disease evolution in patient No. 5. Relapsed on þ10 months
and received haploidentical transplantation at þ10.5 months, second
relapsed at þ17.5 months and immediately received chemotherapy.Pattern of chimerism in one T-ALL, one T/NK-ALL,
and one NHL patient
Monitoring of lineage-specific chimerism was also
made in three patients who suffered from lymphocyte-
related diseases and received allo-HSCT. In the early
period post HSCT, the three patients showed similar
donor% of the T-, B- and NK cell lineages; <5%
discrepancy between the three subsets. One patient
with T/NK-ALL relapsed at four months, and a more
rapid decreasing MC level in T/NK-cells than in B-
cells was observed (T-cells 58.7%, NK-cells 54%, B-
cells 81.7%).
Discussion
As patient management guidance, chimerism anal-
ysis plays an irreplaceable role, confirming complete
engraftment and helping to prevent graft failure or10 12 14 16 18 20
0
20
40
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80
100
relapse +
chemotherapy
do
no
r %
Time after transplatation(month)
B
T
 NK
relapse +
chemotherapy
Fig. 4. Disease evolution in patient No. 14, Relapsed at þ13.5
months and þ16.5 months and immediately received chemotherapy.
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prone to monitor chimerism in nonmyeloablative
(NMA) and reduced-intensity conditioning (RIC)
HSCT patients.11,12,15,16 Since most patients undergo-
ing myeloablative (MA) HSCT rapidly achieve com-
plete chimerism,17 it is generally believed that it is not
necessary to detect chimerism in patients after mye-
loablative HSCT. However, in a recent study, Mick-
elson18 found that the median time to reach CC showed
no difference between the NMA and MA groups. The
results in our study verified the importance of chime-
rism analysis in MA patients.
In order to increase the sensitivity of chimerism
analysis, many studies have examined the level of
mixed chimerism of different cell subsets for early
prediction of graft failure or of relapse; especially in
NMA- or RIC-HCT cases. The majority of these
studies showed that T-cells (from PB) are the most
valuable prognostic fraction for predicting complete
engraftment.6,12e14,16 However, one recent study
reached a different conclusion.18 The possible reasons
for this controversy are differences in underlying dis-
ease, conditioning regimen, and graft source. Thus, the
determination of lineage-specific chimerism is very
important in patients with malignancies as the original
disease.19 Since the kinetics of B-cell chimerism in B-
ALL has rarely been reported in prior research,19,20 we
monitored B cell (from BM) chimerism post-HSCT,
compared the dynamic change in B-cells with T- and
NK-cell lineages, and found some interesting results.
In the early period after allo-HSCT, the develop-
ment of complete donor chimerism varied between cell
lineages. In the majority of patients, CC appeared first
in NK-cells followed by T-cells, while B-cells lagged
behind T-cells. Although the number of patients with
MC in the B-cell and T-cell compartments was similar
in the early period post HSCT, the donor% of the two
cell lines was notably different (Fig. 1). For instance,
patient No. 20 did not achieve B-cell CC until þ3
months, while she achieved T/NK-cell CC at þ1
month. Moreover, a later establishment of B-cell CC
was also observed in the three relapsed patients who
received further therapy (Figs. 2e4). In the graft
rejection phase and with recurrent disease, detection of
B-cell chimerism seemed to show higher sensitivity
than T and NK cell chimerism. Graft rejection was
experienced by five patients. The frequency of patients
with decreasing MC in B-, T-, and NK-cell subsets
were 5/5, 2/5 and 2/5, respectively. When disease
relapsed, five patients showed a faster decreasing
donor% of B-cells than of T-cells or NK-cells. It is
interesting that patient No. 4 displayed a more rapiddecrease in NK-cells than in T-cells or B-cells. This
observation might be partly explained by the fact that
we missed the opportunity to monitor donor% de-
creases earlier during relapse.
During this analysis, we also monitored chimerism
in one T-ALL, one T/NK-ALL and one NHL adult
patient who had received myeloablative transplants.
The T/NK-ALL patient relapsed at four months, and
the other two patients, T-ALL and NHL, were still in
disease-free state at þ32 and þ24 months. It was
observed that in the early engraftment, donor% in B-
and T-cell lineages showed no difference, CC in these
two cell lineages lagged behind NK-cell CC. When
disease relapsed, a faster decreasing MC was seen only
in the T and NK cell lineages, but there was no dif-
ference in the donor% between the T-cells and NK-
cells.
Most of previous studies focused on the association
between the chimerism status in T- or NK-cells and
clinical outcomes such as GVHD, relapse and sur-
vival.21,22 Due to the small number of patients included
in this pilot study, we were not able to show any
relationship between them. The characterization of the
chimerism status in T and NK subsets was basically in
concordance with the majority of recent published
studies. However, we found that in 4 of 6 relapsed
patients, the donor% of NK-cells decreased more
rapidly than the donor% of T-cells. The evolution of B-
cell chimerism in our patients is quite interesting.
Monitoring of B-cell chimerism post SCT seems to be
valuable and its sensitivity may be higher than for T-
cells or NK-cells in chimerism analysis. These obser-
vations support the hypothesis that we can assess B-
cell chimerism to insure complete engraftment and to
anticipate graft rejection and relapse in B-ALL pa-
tients. However, this notion has to be interpreted with
great caution and certainly requires further assessment.
For post-transplantation chimerism monitoring, the
better modes are intensive and follow multiple lineages
with STR or other quantitative techniques, especially
in those lacking other suitable disease markers.
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